Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
Standard
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. / Düngen, Hans-Dirk; Apostolovic, Svetlana; Inkrot, Simone; Tahirovic, Elvis; Töpper, Agnieszka; Mehrhof, Felix; Prettin, Christiane; Putnikovic, Biljana; Neskovic, Aleksandar N; Krotin, Mirjana; Sakac, Dejan; Lainscak, Mitja; Edelmann, Frank; Wachter, Rolf; Rau, Thomas; Eschenhagen, Thomas; Doehner, Wolfram; Anker, Stefan D; Waagstein, Finn; Herrmann-Lingen, Christoph; Gelbrich, Goetz; Dietz, Rainer; Investigators, CIBIS-ELD; Failure, Project Multicentre Trials In The Competence Network Heart.
In: EUR J HEART FAIL, Vol. 13, No. 6, 6, 2011, p. 670-680.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
AU - Düngen, Hans-Dirk
AU - Apostolovic, Svetlana
AU - Inkrot, Simone
AU - Tahirovic, Elvis
AU - Töpper, Agnieszka
AU - Mehrhof, Felix
AU - Prettin, Christiane
AU - Putnikovic, Biljana
AU - Neskovic, Aleksandar N
AU - Krotin, Mirjana
AU - Sakac, Dejan
AU - Lainscak, Mitja
AU - Edelmann, Frank
AU - Wachter, Rolf
AU - Rau, Thomas
AU - Eschenhagen, Thomas
AU - Doehner, Wolfram
AU - Anker, Stefan D
AU - Waagstein, Finn
AU - Herrmann-Lingen, Christoph
AU - Gelbrich, Goetz
AU - Dietz, Rainer
AU - Investigators, CIBIS-ELD
AU - Failure, Project Multicentre Trials In The Competence Network Heart
PY - 2011
Y1 - 2011
N2 - Various beta-blockers with distinct pharmacological profiles are approved in heart failure, yet they remain underused and underdosed. Although potentially of major public health importance, whether one agent is superior in terms of tolerability and optimal dosing has not been investigated. The aim of this study was therefore to compare the tolerability and clinical effects of two proven beta-blockers in elderly patients with heart failure.
AB - Various beta-blockers with distinct pharmacological profiles are approved in heart failure, yet they remain underused and underdosed. Although potentially of major public health importance, whether one agent is superior in terms of tolerability and optimal dosing has not been investigated. The aim of this study was therefore to compare the tolerability and clinical effects of two proven beta-blockers in elderly patients with heart failure.
KW - Humans
KW - Male
KW - Female
KW - Treatment Outcome
KW - Europe
KW - Double-Blind Method
KW - Dose-Response Relationship, Drug
KW - Adrenergic beta-Antagonists/adverse effects/therapeutic use
KW - Aged
KW - Bisoprolol/adverse effects/therapeutic use
KW - Carbazoles/adverse effects/therapeutic use
KW - Forced Expiratory Volume/drug effects
KW - Heart Failure/drug therapy/physiopathology
KW - Heart Rate/drug effects
KW - Propanolamines/adverse effects/therapeutic use
KW - Humans
KW - Male
KW - Female
KW - Treatment Outcome
KW - Europe
KW - Double-Blind Method
KW - Dose-Response Relationship, Drug
KW - Adrenergic beta-Antagonists/adverse effects/therapeutic use
KW - Aged
KW - Bisoprolol/adverse effects/therapeutic use
KW - Carbazoles/adverse effects/therapeutic use
KW - Forced Expiratory Volume/drug effects
KW - Heart Failure/drug therapy/physiopathology
KW - Heart Rate/drug effects
KW - Propanolamines/adverse effects/therapeutic use
M3 - SCORING: Journal article
VL - 13
SP - 670
EP - 680
JO - EUR J HEART FAIL
JF - EUR J HEART FAIL
SN - 1388-9842
IS - 6
M1 - 6
ER -